Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BioMarck Pharmaceuticals Ltd.

This article was originally published in Start Up

Executive Summary

BioMarck Pharmaceuticals is studying the role of the MARCKS protein (myristoylated alanine-rich C kinase substrate) in chronic obstructive pulmonary disease and diseases like asthma and cystic fibrosis. In each of these diseases, excessive amounts of mucus are secreted, which leads to obstruction of the lung airways. Experiments in mice showed that inhibiting the protein led to decreased mucus secretion, reduced inflammation in the lungs, and improvements in lung air flow.

You may also be interested in...



A Brighter Outlook for New Cystic Fibrosis Drugs

The pipeline of new medicines to combat cystic fibrosis has risen dramatically thanks to funding support from philanthropic organizations such as the Cystic Fibrosis Foundation and venture capitalists. As more compounds demonstrate proof-of-concept, look for Big Pharma to move into the area too, lured by the possibility of label expansion beyond CF into more widespread diseases such as asthma and COPD.

Start-Up Previews (05/2008)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "A Brighter Outlook for Cystic Fibrosis Drugs," features profiles of APT Pharmaceuticals, Aridis, and BioMarck Pharmaceuticals. Plus these Start-Ups Across Health Care: Cannasat, Nanobiotix, Reveal Sciences, and Vertebration.

A Brighter Outlook for New Cystic Fibrosis Drugs

The pipeline of new medicines to combat cystic fibrosis has risen dramatically thanks to funding support from philanthropic organizations such as the Cystic Fibrosis Foundation and venture capitalists. As more compounds demonstrate proof-of-concept, look for Big Pharma to move into the area too, lured by the possibility of label expansion beyond CF into more widespread diseases such as asthma and COPD.

Related Companies

UsernamePublicRestriction

Register

SC091584

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel